Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

With ALKEM's revenues expected to fall below the previous year's, investors are likely to approach the stock with caution. Declining revenues can negatively affect profitability, which makes it harder for the company to maintain investor confidence and perform well in the market.

Financial Ratios:

currentRatio 0.00000
forwardPE 25.74258
debtToEquity 12.40900
earningsGrowth 0.05200
revenueGrowth 0.01500
grossMargins 0.63008
operatingMargins 0.19978
trailingEps 180.10000
forwardEps 213.95000

ALKEM's Forward PE being in a reasonable range suggests the stock is fairly priced based on its earnings. The stock isn't overpriced, leaving room for growth, making it an attractive investment for those seeking opportunities for future value appreciation.
ALKEM's low Debt-to-Equity ratio indicates the company is not over-leveraged. By limiting its dependence on debt, ALKEM reduces its financial risk and demonstrates a strong capital structure, making it a more stable investment option for those wary of excessive borrowing.
Alkem Laboratories Limited's negative gross and operating margins signal that the company is not profitable, struggling to cover costs associated with production and operations. This could be a red flag for its financial performance moving forward.
With a forward EPS greater than its trailing EPS, ALKEM is expected to see higher profitability this year. The forecasted increase in earnings reflects optimism about the company's financial growth and potential for improved performance over the prior year.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

ALKEM's stock price has consistently been near the lower edge of expected values, indicating potential struggles in meeting growth projections. This trend may reflect a cautious market sentiment toward the company.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


ALKEM has garnered a buy bias from analysts recently, suggesting the stock is a good investment opportunity. This may lead to increased investor interest, as ALKEM is seen as a reliable place to park money for those looking to benefit from potential market gains and company growth.